Cite
HARVARD Citation
Fowler, N. et al. (2021). Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology. 39 (15), pp. 1609-1618. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Fowler, N. et al. (2021). Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology. 39 (15), pp. 1609-1618. [Online].